OSCR
Oscar Health, Inc.
OSCR has the edge over STOK overall, supported by stronger fundamentals and stronger modeled upside.
STOK
Stoke Therapeutics, Inc.
STOK has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STOK Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
STOK's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
STOK PE Valuation
STOK has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
STOK Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect STOK's losses to grow, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over STOK on earnings quality, reporting a profit while its opponent remains loss making.
STOK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.77 | -639% |
| Q2 2026 | -$3.34 | -480% |
| Q1 2026 | -$2.81 | -443% |
| Q4 2025 | -$0.12 | +$1.53 |
| Q3 2025 | $0.70 | +$2.81 |
| Q2 2025 | $0.88 | +$3.07 |
| Q1 2025 | $0.82 | +$3.24 |
| Q4 2024 | -$1.65 | +$0.73 |
STOK has swung to a loss: it lost $3.77 per share over the past year, after a profit the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over STOK on profitability, with a higher operating margin.
STOK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3M | +5.9% |
| Q2 2026 | $9.3M | -33% |
| Q1 2026 | $6.2M | -96% |
| Q4 2025 | $1.4M | -94% |
| Q3 2025 | $10.6M | +117% |
| Q2 2025 | $13.8M | +186% |
| Q1 2025 | $158.6M | +3661% |
| Q4 2024 | $22.6M | +707% |
STOK's revenue is recovering but still below its 2025 peak: $11M last quarter, up 5.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -687% | -282 points |
| Q2 2026 | -702% | -504 points |
| Q1 2026 | -858% | -928 points |
| Q4 2025 | -4382% | -4322 points |
| Q3 2025 | -405% | +208 points |
| Q2 2025 | -198% | +410 points |
| Q1 2025 | 70% | +743 points |
| Q4 2024 | -60% | +996 points |
STOK's operating margin was −687% last quarter, down 282 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over STOK on cash generation, producing positive trailing cash flow while its opponent burns cash.
STOK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$65.5M | -$35M |
| Q2 2026 | -$58.6M | -$33M |
| Q1 2026 | -$60.9M | -146% |
| Q4 2025 | -$30.7M | -$7.5M |
| Q3 2025 | -$30.5M | -$8.8M |
| Q2 2025 | -$25.6M | -$8.1M |
| Q1 2025 | $131.7M | +$156.3M |
| Q4 2024 | -$23.2M | -$2.4M |
STOK has burned cash in almost every quarter: −$216M over the past year, against $52M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STOK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +2.3M shares |
| 1 year | +17% | +9.8M shares |
| 3 years | +54% | +24.1M shares |
| 5 years | +86% | +31.6M shares |
| Available history | +108% | +35.5M shares |
STOK has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
STOK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -2.9x | Net Cash |
| Q2 2025 | -2.4x | Net Cash |
| Q1 2025 | -6.8x | Net Cash |
STOK has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STOK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 36.1 | Neutral |
STOK's weekly RSI is 43 (neutral) and its Stochastic is 36 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STOK PE vs Healthcare Sector
| Metric | STOK | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
STOK has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STOK on trend strength, trading above more of its moving averages.
STOK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.4 | 3.1% above |
| 20 week MA | $28.5 | 8% below |
| 50 week MA | $30.7 | 15% below |
| 100 week MA | $22.9 | 14% above |
| 200 week MA | $16.2 | 61% above |
STOK's trend is mixed: it's above three of its five weekly moving averages, and 61% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STOK on returns for 2026, with the stronger performance.
STOK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.6 | $58.3 | +119% |
| 2021 | $58.3 | $21.6 | -63% |
| 2022 | $21.6 | $8.30 | -62% |
| 2023 | $8.30 | $5.26 | -37% |
| 2024 | $5.26 | $11.1 | +110% |
| 2025 | $11.1 | $31.9 | +189% |
| 2026 YTD | $31.9 | $26.2 | -18% |
STOK's yearly returns have swung widely, from +189% in 2025 to −63% in 2021. It's down 18% so far in 2026.